Skip to main content

#Coronavirus Disease Research #References (by AMEDEO, Jan. 24 '26)

Image
By G.M.

 


    Antiviral Res

  1. HEDSKOG C, Rodriguez L, Hu Y, Li J, et al
    SARS-CoV-2 Resistance Analyses From the Phase 3 BIRCH Study of Obeldesivir in High-Risk Nonhospitalized Participants With COVID-19.
    Antiviral Res. 2026 Jan 19:106351. doi: 10.1016/j.antiviral.2026.106351.
    PubMed         Abstract available


    BMJ

  2. HIGGS J
    Help me piece my story together.
    BMJ. 2026;392:r2624.
    PubMed        

  3. RUSSELL MD, Schaffer A, Bechman K, Gibson M, et al
    Time trends in newly recorded diagnoses of 19 long term conditions before, during, and after the covid-19 pandemic: population based cohort study in England using OpenSAFELY.
    BMJ. 2026;392:e086393.
    PubMed         Abstract available


    Clin Infect Dis

  4. WINOKUR P, Diya O, Fitz-Patrick D, Dever M, et al
    Safety and Immunogenicity of a Fourth Dose of Omicron-BA.1-Adapted BNT162b2 COVID-19 Vaccines in Adults 18?55 Years Old.
    Clin Infect Dis. 2026 Jan 21:ciag026. doi: 10.1093.
    PubMed         Abstract available


    Emerg Infect Dis

  5. FORD ND, Simeone RM, Pratt C, Saydah S, et al
    Functional Limitations and Illness-Related Absenteeism among School-Aged Children with and without Long COVID, United States, 2022-2023.
    Emerg Infect Dis. 2025;31:11-19.
    PubMed         Abstract available

  6. PRATT CQ, Dalton AF, Koumans EH, Agedew A, et al
    Thrombotic Events and Stroke in the Year After COVID-19 or Other Acute Respiratory Infection.
    Emerg Infect Dis. 2025;31:3-10.
    PubMed         Abstract available

  7. LEIS AM, Womack KN, Maxcy C, Caldwell E, et al
    Long-Term Illness in Adults Hospitalized for Respiratory Syncytial Virus Disease, United States, February 2022-September 2023.
    Emerg Infect Dis. 2025;31:20-29.
    PubMed         Abstract available

  8. FIORE AE
    Progress Toward Understanding Infection-Associated Chronic Conditions and Illnesses.
    Emerg Infect Dis. 2025;31:1-2.
    PubMed        

  9. GRAY GC, Vlasova AN, Lednicky JA, Nguyen-Tien T, et al
    Emerging Respiratory Virus Threats from Influenza D and Canine Coronavirus HuPn-2018.
    Emerg Infect Dis. 2026;32.
    PubMed         Abstract available


    Int J Infect Dis

  10. OSWIN HP, Tellier R, Groth R, Silvonen V, et al
    Quantification of airborne respiratory microflora provides insights into airborne infection risk.
    Int J Infect Dis. 2026 Jan 19:108403. doi: 10.1016/j.ijid.2026.108403.
    PubMed         Abstract available

  11. UEMATSU T, Nojiri S, Nagao M, Ishijima M, et al
    Comprehensive analysis of risk factors for Coronavirus disease 2019 infection and post-infection sequelae based on real-world data from a health insurance database in Japan.
    Int J Infect Dis. 2026 Jan 19:108405. doi: 10.1016/j.ijid.2026.108405.
    PubMed         Abstract available


    J Med Virol

  12. MANICA M, Giombini E, Del Manso M, Molina Grane C, et al
    Integrated Genomic and Epidemiological Surveillance to Monitor SARS-CoV-2 Variants in Italy: Insights From the JN.1 Case Study (2023-2024).
    J Med Virol. 2026;98:e70775.
    PubMed         Abstract available

  13. YANG X, Liu Q, Li Y, Lee JZ, et al
    Establishment of a Point-of-Care Testing Method for Rapid Detection of Multiple Respiratory Virus Antigens Based on a Dual-Drive Microfluidic Chip.
    J Med Virol. 2026;98:e70811.
    PubMed         Abstract available


    J Virol

  14. TIEN C-F, Lin E-J, Tsai W-H, Tsai W-T, et al
    SARS-CoV-2 spike protein expression drives post-acute coagulopathy.
    J Virol. 2026 Jan 21:e0125525. doi: 10.1128/jvi.01255.
    PubMed         Abstract available


    Lancet

  15. PETO J
    The UK COVID-19 Inquiry and the next pandemic.
    Lancet. 2026;407:220-221.
    PubMed        


    Nature


  16. AI and nuclear energy feature strongly in agenda-setting technologies for 2026.
    Nature. 2026;649:799.
    PubMed        


    Science

  17. KUSCH C, Stegner D, Weiss LJ, Nurden P, et al
    Platelet-derived integrin- and tetraspanin-enriched tethers exacerbate severe inflammation.
    Science. 2026;391:eadu2825.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »